A#2545 IV SEC for SpA #ACR23 @Rheumow Approved by FDA, though diff dose Who: Medicare/cost/QoL benefit for IV or obese (
Tweet Content
A#2545 IV SEC for SpA #ACR23 @Rheumow
Approved by FDA, though diff dose
Who: Medicare/cost/QoL benefit for IV or obese (wt based dose)
W16: 41% ASAS40 v 23% PBO
W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%)
SAE 6%, discontinuation 3.5%
#ACRBest https://t.co/ruW0ys49gk
Show on Archive Page
On
Display in Search Results
On
PDQ
Off